PCSK9 function and physiology

Journal of Lipid Research

Volumn 49, Issue 6, 2008, Pages 1152-1156

  Peterson, Andrew S ^a   Fong, Loren G ^b   Young, Stephen G ^b  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHOLESTEROL; EPIDERMAL GROWTH FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; RECOMBINANT PROTEIN; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN, HUMAN; PCSK9 PROTEIN, MOUSE;

ADRENAL GLAND; CATALYSIS; CELL SURFACE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ENDOSOME; GENE EXPRESSION; HUMAN; HYDROGEN BOND; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LYSOSOME; MISSENSE MUTATION; NONHUMAN; NOTE; PARABIOSIS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; UPREGULATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE; METABOLISM; MOUSE;

ANIMALS; CATALYTIC DOMAIN; HUMANS; MICE; MODELS, MOLECULAR; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 48549091854     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E800008-JLR200     Document Type: Note

References (38)

1. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
2. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
3. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
4. Brown, M. S., and J. L. Goldstein. 1983. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J. Clin. Invest. 72: 743-747.
5. Goldstein, J. L., and M. S. Brown. 1977. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46: 897-930.
6. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
7. Berge, K. E., L. Ose, and T. P. Leren. 2006. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26: 1094-1100.
8. Kotowski, I. K., A. Pertsemlidis, A. Luke, R. S. Cooper, G. L. Vega, J. C. Cohen, and H. H. Hobbs. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78: 410-422.
9. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
10. Cohen, J., A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia, and H. H. Hobbs. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37: 161-165.
11. Zhao, Z., Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79: 514-523.
12. Pandit, S., D. Wisniewski, J. C. Santoro, S. Ha, V. Ramakrishnan, R. M. Cubbon, R. T. Cummings, S. D. Wright, C. P. Sparrow, A. Sitlani, and T. S. Fisher. 2008. Functional Analysis of Sites within PCSK9 Responsible for Hypercholesterolemia. J. Lipid Res. 49: 1333-1343.
13. Grefhorst, A., M. C. McNutt, T. A. Lagace, and J. D. Horton. 2008. Plasma PCSK9 Preferentially Reduces Liver LDL Receptors in Mice. J. Lipid Res. 49: 1303-1311.
14. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933.
15. Horton, J. D., N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park, M. S. Brown, and J. L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA. 100: 12027-12032.
16. Maxwell, K. N., R. E. Soccio, E. M. Duncan, E. Sehayek, and J. L. Breslow. 2003. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44: 2109-2119. (Pubitemid 37509626)
17. Maxwell, K. N., E. A. Fisher, and J. L. Breslow. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a postendoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA. 102: 2069-2074.
18. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116: 2995-3005.
19. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
20. Hallman, D. M., S. R. Srinivasan, W. Chen, E. Boerwinkle, and G. S. Berenson. 2007. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am. J. Cardiol. 100: 69-72. (Pubitemid 46961903)
21. Cameron, J., O. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge, and T. P. Leren. 2006. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15: 1551-1558.
22. Brown, M. S., and J. L. Goldstein. 2006. Biomedicine. Lowering LDL-not only how low, but how long? Science. 311: 1721-1723.
23. Hooper, A. J., A. D. Marais, D. M. Tanyanyiwa, and J. R. Burnett. 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 193: 445-448. (Pubitemid 47058112)
24. Hampton, E. N., M. W. Knuth, J. Li, J. L. Harris, S. A. Lesley, and G. Spraggon. 2007. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. USA. 104: 14604-14609.
25. Piper, D. E., S. Jackson, Q. Liu, W. G. Romanow, S. Shetterly, S. T. Thibault, B. Shan, and N. P. Walker. 2007. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 15: 545-552. (Pubitemid 46702689)
26. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105: 1820-1825.
27. McNutt, M. C., T. A. Lagace, and J. D. Horton. 2007. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282: 20799-20803.
28. Zhang, D. W., T. A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2007. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282: 18602-18612.
29. Fisher, T. S., P. Lo Surdo, S. Pandit, M. Mattu, J. C. Santoro, D. Wisniewski, R. T. Cummings, A. Calzetta, R. M. Cubbon, P. A. Fischer, et al. 2007. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem. 282: 20502-20512.
30. Davis, C. G., J. L. Goldstein, T. C. Sudhof, R. G. Anderson, D. W. Russell, and M. S. Brown. 1987. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature. 326: 760-765. (Pubitemid 17057795)
31. Rudenko, G., L. Henry, K. Henderson, K. Ichtchenko, M. S. Brown, J. L. Goldstein, and J. Deisenhofer. 2002. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 298: 2353-2358. (Pubitemid 36014201)
32. van der Westhuyzen, D. R., M. L. Stein, H. E. Henderson, A. D. Marais, A. M. Fourie, and G. A. Coetzee. 1991. Deletion of two growth-factor repeats from the low-density-lipoprotein receptor accelerates its degradation. Biochem. J. 277: 677-682.
33. Alborn, W. E., G. Cao, H. E. Careskey, Y. W. Qian, D. R. Subramaniam, J. Davies, E. M. Conner, and R. J. Konrad. 2007. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin. Chem. 53: 1814-1819.
34. Careskey, H. E., R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad. 2008. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49: 394-398.
35. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459.
36. Crooke, R. M., M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera. 2005. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46: 872-884. (Pubitemid 43309212)
37. Kastelein, J. J., M. K. Wedel, B. F. Baker, J. Su, J. D. Bradley, R. Z. Yu, E. Chuang, M. J. Graham, and R. M. Crooke. 2006. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 114: 1729-1735. (Pubitemid 44607121)
38. Graham, M. J., K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke. 2007. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48: 763-767. (Pubitemid 46557881)